Welcome to the GoodRx third-quarter 2024 earnings call. As a reminder, today's conference call is being recorded. I would now ...

GoodRx (NASDAQ:GDRX – Get Free Report) had its price target lowered by Barclays from $10.00 to $6.00 in a research note ...

On Monday, Goodrx Holdings Inc (GDRX) stock saw a modest uptick, ending the day at $4.89 which represents no change from the prior close of of $4.89. The stock opened at $4.98 and touched a low of $4.

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.06 per share a year ago.

In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on GoodRx Holdings (GDRX – Research Report), ...

Raymond James has recently raised Goodrx Holdings Inc (GDRX) stock to Strong Buy rating, as announced on August 9, 2024, according to Finviz. Earlier, on May 23, 2024, RBC Capital Mkts had raised the ...

Barclays lowered the firm’s price target on GoodRx (GDRX) to $6 from $10 and keeps an Overweight rating on the shares post the Q3 report.

GoodRx Holdings Inc (GDRX) reports robust growth in adjusted EBITDA and Pharma Manufacturer Solutions revenue, despite facing ...

GoodRx's revenue growth is decelerating, with significant reliance on retail partnerships and cyclical transactional revenue, ...

While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics ...